SELLAS Life Sciences (SLS) Other Accumulated Expenses (2011 - 2017)
SELLAS Life Sciences' (SLS) quarterly Other Accumulated Expenses came in at $191000.0 in Q4 2017, down 15.86% year-on-year from $227000.0 in Q4 2016, and down 15.86% on a QoQ basis from $227000.0 in Q4 2016.
SELLAS Life Sciences (SLS) Other Accumulated Expenses (2011 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 3 years of Other Accumulated Expenses data on file, last reported at $191000.0 in Q4 2017.
- On a quarterly basis, Other Accumulated Expenses fell 15.86% year-over-year to $191000.0 in Q4 2017; TTM through Dec 2017 was $191000.0, a 15.86% decrease from a year earlier, with the FY2017 full-year figure at $191000.0, down 15.86% from the prior year.
- Other Accumulated Expenses for Q4 2017 stood at $191000.0, down from $227000.0 in the prior quarter.
- Over the last five years, Other Accumulated Expenses for SLS reached as high as $227000.0 in Q4 2016 and fell as low as $191000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 191,000.00 |
| Dec 31, 2016 | 227,000.00 |
| Dec 31, 2011 | 25,000.00 |